CDC37 is a molecular chaperone that physically stabilizes the catalytic domains found in protein kinases and is therefore a wide-spectrum regulator of protein phosphorylation. It is also an overexpressed oncoprotein that mediates carcinogenesis by stabilizing the compromised structures of mutant and/or overexpressed oncogenic kinases. Recent work shows that such dependency of malignant cells on increased CDC37 expression is a vulnerability that can be targeted in cancer by agents that deplete or inhibit CDC37. CDC37 is thus a candidate for broad-spectrum molecular cancer therapy.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nature Rev. Cancer 5, 761–772 (2005).
Pearl, L. H. Hsp90 and Cdc37 — a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 15, 55–61 (2005).
Calderwood, S. K., Khaleque, M. A., Sawyer, D. B. & Ciocca, D. R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 31, 164–172 (2006).
Neckers, L. & Ivy, S. P. Heat shock protein 90. Curr. Opin. Oncol. 15, 419–424 (2003).
Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 10, 47–51 (2004).
Stepanova, L. et al. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19, 2186–2193 (2000).
Vaughan, C. K. et al. Structure of an Hsp90–Cdc37–Cdk4 complex. Mol. Cell 23, 697–707 (2006).
Caplan, A. J., Ma'ayan, A. & Willis, I. M. Multiple kinases and system robustness: a link between Cdc37 and genome integrity. Cell Cycle 6, 3145–3147 (2007).
Caplan, A. J., Mandal, A. K. & Theodoraki, M. A. Molecular chaperones and protein kinase quality control. Trends Cell Biol. 17, 87–92 (2007).
Mandal, A. K. et al. Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation. J. Cell Biol. 176, 319–328 (2007).
Reed, S. I. The selection of S. cerevisiae mutants defective in the start event of cell division. Genetics 95, 561–577 (1980).
Pascale, R. M. et al. Role of HSP90, CDC37, and CRM1 as modulators of P16INK4A activity in rat liver carcinogenesis and human liver cancer. Hepatology 42, 1310–9 (2005).
Prince, T., Sun, L. & Matts, R. L. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry 44, 15287–15295 (2005).
Stepanova, L., Finegold, M., DeMayo, F., Schmidt, E. V. & Harper, J. W. The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol. Cell Biol. 20, 4462–4473 (2000).
Schwarze, S. R., Fu, V. X. & Jarrard, D. F. Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Res. 63, 4614–4619 (2003).
Robzyk, K. et al. Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Mol. Cell. Endocrinol. 268, 767–774 (2007).
Shao, J., Prince, T., Hartson, S. D. & Matts, R. L. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J. Biol. Chem. 278, 38117–38120 (2003).
Miyata, Y. & Nishida, E. CK2 binds, phosphorylates, and regulates its pivotal substrate Cdc37, an Hsp90-cochaperone. Mol. Cell Biochem. 274, 171–179 (2005).
Turnbull, E. L., Martin, I. V. & Fantes, P. A. Cdc37 maintains cellular viability in Schizosaccharomyces pombe independently of interactions with heat-shock protein 90. FEBS J. 272, 4129–4140 (2005).
MacLean, M. & Picard, D. Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones 8, 114–119 (2003).
Cox, M. B. et al. Fkbp52 phosphorylation: a potential mechanism for regulating steroid hormone receptor activity. Mol. Endocrinol. (2007).
Prince, T. & Matts, R. L. Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37. J. Biol. Chem. 279, 39975–39981 (2004).
Prince, T. & Matts, R. L. Exposure of protein kinase motifs that trigger binding of Hsp90 and Cdc37. Biochem. Biophys. Res. Commun. 338, 1447–1454 (2005).
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Stepanova, L., Leng, X., Parker, S. B. & Harper, J. W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10, 1491–502 (1996).
Waza, M. et al. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J. Mol. Med. 84, 635–646 (2006).
Kamal, A. et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407–410 (2003).
Theodoraki, M. A., Kunjappu, M., Sternberg, D. W. & Caplan, A. J. Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context. Exp. Cell Res. (2007).
Thompson, M. A. et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum. Pathol. 36, 494–504 (2005).
Katayama, Y. et al. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells. Int. J. Oncol. 25, 579–595 (2004).
Feo, F. et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim. Biophys. Acta 1765, 126–147 (2006).
Casas, S. et al. Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genet. Cytogenet. 146, 89–101 (2003).
Gaboli, M. et al. Mzf1 controls cell proliferation and tumorigenesis. Genes Dev. 15, 1625–1630 (2001).
Zou, J., Guo, Y., Guettouche, T., Smith, D. F. & Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471–480 (1998).
Gray, P. J. Jr, Stevenson, M. A. & Calderwood, S. K. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 67, 11942–11950 (2007).
Zaarur, N., Gabai, V. L., Porco, J. A. Jr, Calderwood, S. & Sherman, M. Y. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 66, 1783–1791 (2006).
Roiniotis, J., Masendycz, P., Ho, S. & Scholz, G. M. Domain-mediated dimerization of the Hsp90 cochaperones Harc and Cdc37. Biochemistry 44, 6662–6669 (2005).
Holmes, J. L., Sharp, S. Y., Hobbs, S. & Workman, P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 68, 1188–1197 (2008).
Zhang, T. et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7, 162–170 (2008).
We acknowledge the support of the Department of Radiation Oncology at Beth Israel Deaconess Medical Center. These studies were also supported by National Institutes of Health grants 5RO1CA047407 and 3RO1CA094397 (S.K.C.) and a Howard Hughes Medical Institute Medical Student Research Training Fellowship (P.J.G.). Because of space limitations we were unable to cite many significant studies on CDC37 and HSP90. We apologize to the authors of such studies and refer the readers to excellent publications that cite the literature more inclusively (Refs 1,2,3,5,9,10
About this article
Cite this article
Gray, P., Prince, T., Cheng, J. et al. Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 8, 491–495 (2008). https://doi.org/10.1038/nrc2420
FKBP4 integrates FKBP4/Hsp90/IKK with FKBP4/Hsp70/RelA complex to promote lung adenocarcinoma progression via IKK/NF-κB signaling
Cell Death & Disease (2021)
The functions and regulation of heat shock proteins; key orchestrators of proteostasis and the heat shock response
Archives of Toxicology (2021)
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Signal Transduction and Targeted Therapy (2020)
Journal of Hematology & Oncology (2018)
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
Acta Pharmacologica Sinica (2016)